-
Viral Immunology Mar 2018Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV)... (Review)
Review
Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV) vaccine was developed empirically by attenuation of wild-type (WT) MeV by in vitro passage in human and chicken cells and licensed in 1963. Additional passages led to further attenuation and the successful vaccine strains in widespread use today. Attenuation is associated with decreased replication in lymphoid tissue, but the molecular basis for this restriction has not been identified. The immune response is age dependent, inhibited by maternal antibody (Ab) and involves induction of both Ab and T cell responses that resemble the responses to WT MeV infection, but are lower in magnitude. Protective immunity is correlated with levels of neutralizing Ab, but the actual immunologic determinants of protection are not known. Because measles is highly transmissible, control requires high levels of population immunity. Delivery of the two doses of vaccine needed to achieve >90% immunity is accomplished by routine immunization of infants at 9-15 months of age followed by a second dose delivered before school entry or by periodic mass vaccination campaigns. Because delivery by injection creates hurdles to sustained high coverage, there are efforts to deliver MeV vaccine by inhalation. In addition, the safety record for the vaccine combined with advances in reverse genetics for negative strand viruses has expanded proposed uses for recombinant versions of measles vaccine as vectors for immunization against other infections and as oncolytic agents for a variety of tumors.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Disease Transmission, Infectious; Drug Discovery; Humans; Immunization Schedule; Measles; Measles Vaccine; Measles virus; Serial Passage; Technology, Pharmaceutical; Vaccines, Attenuated
PubMed: 29256824
DOI: 10.1089/vim.2017.0143 -
Cleveland Clinic Journal of Medicine Jun 2019Although a safe and effective vaccine has been available for over 6 decades, vaccine hesitancy in the United States and social and political unrest globally have led to... (Review)
Review
Although a safe and effective vaccine has been available for over 6 decades, vaccine hesitancy in the United States and social and political unrest globally have led to undervaccination. As a result, in recent months, vaccine control of measles has been threatened with an alarming upswing in measles cases nationally and internationally. Here, we review the disease and its management in view of recent outbreaks.
Topics: Disease Outbreaks; Humans; Measles; Measles Vaccine; United States; Vaccine-Preventable Diseases
PubMed: 31204978
DOI: 10.3949/ccjm.86a.19065 -
Human Vaccines & Immunotherapeutics 2015Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was... (Review)
Review
Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was largely contained by the development of a live attenuated vaccine that was introduced into the vaccination programs. However, all efforts to eradicate the disease failed and continued to annually result in significant deaths. The development of molecular biology techniques allowed the rescue of MV from cDNA that enabled important insights into a variety of aspects of the biology of the virus and its pathogenesis. Subsequently these technologies facilitated the development of novel vaccine candidates that induce immunity against measles and other pathogens. Based on the promising prospective, the use of MV as a recombinant vaccine and a therapeutic vector is addressed.
Topics: Drug Carriers; Genetic Vectors; Humans; Measles; Measles Vaccine; Measles virus; Oncolytic Virotherapy; Vaccines, Attenuated; Vaccines, Synthetic
PubMed: 25483511
DOI: 10.4161/hv.34298 -
Medicina 2020
Topics: Anti-Vaccination Movement; Humans; Mass Vaccination; Measles; Measles Vaccine
PubMed: 32044749
DOI: No ID Found -
CMAJ : Canadian Medical Association... Apr 2024
Topics: Humans; Measles; Measles Vaccine
PubMed: 38649173
DOI: 10.1503/cmaj.240415 -
Nature Reviews. Microbiology Dec 2006Measles remains a leading vaccine-preventable cause of child mortality worldwide, particularly in sub-Saharan Africa where almost half of the estimated 454,000 measles... (Review)
Review
Measles remains a leading vaccine-preventable cause of child mortality worldwide, particularly in sub-Saharan Africa where almost half of the estimated 454,000 measles deaths in 2004 occurred. However, great progress in measles control has been made in resource-poor countries through accelerated measles-control efforts. The global elimination of measles has been debated since measles vaccines were first licensed in the 1960's, and this debate is likely to be renewed if polio virus is eradicated. This review discusses the pathogenesis of measles and the likelihood of the worldwide elimination of this disease.
Topics: Animals; Demography; Disease Reservoirs; Emigration and Immigration; Female; Global Health; HIV Infections; Humans; Immunization Programs; Infant; Infant, Newborn; Measles; Measles Vaccine; Measles virus; Public Opinion; Warfare
PubMed: 17088933
DOI: 10.1038/nrmicro1550 -
CMAJ : Canadian Medical Association... Apr 2024
Topics: Humans; Measles; Measles Vaccine; Vaccination; Canada
PubMed: 38649166
DOI: 10.1503/cmaj.240371 -
Vaccine Apr 2023This paper reviews the administration related to vaccination in Japan after the enactment of the Immunization Act in 1948, under which vaccination was implemented... (Review)
Review
This paper reviews the administration related to vaccination in Japan after the enactment of the Immunization Act in 1948, under which vaccination was implemented mandatory for the public. To enhance the effectiveness of vaccination activities, the government implemented group vaccination, which is convenient for vaccinating recipients all at once. In 1976, Japan established the relief system for health damage after vaccination. While some projects, such as the mass administration of live oral polio vaccine in 1961, achieved excellent results, incidents leading to health damage occurred, such as the diphtheria toxoid immunization incident (1948) and frequent occurrence of aseptic meningitis owing to the measles, mumps, and rubella vaccine (1989). In December 1992, the Tokyo High Court sentenced that the onset of health damage after vaccination could be attributed to the negligence of the national government. In the revision of the Immunization Act in 1994, the "mandatory vaccination" enforced until then was changed to "recommended vaccination." The Act was also changed to recommend "individual vaccination" in principle, which is performed after primary care physicians investigate the physical condition of individual recipients and carefully conduct preliminary examination. For approximately 20 years from the 1990s, a vaccine gap existed between Japan and other countries. From around 2010, efforts have been made to bridge this gap and establish the global standard in vaccination.
Topics: Humans; Japan; Rubella Vaccine; Vaccination; Mumps Vaccine; Measles Vaccine; Measles; Mumps; Measles-Mumps-Rubella Vaccine; Rubella
PubMed: 36933981
DOI: 10.1016/j.vaccine.2023.03.020 -
Indian Journal of Medical Ethics 2007
Topics: Developing Countries; Drug Costs; Health Services Needs and Demand; Humans; Infant; Measles; Measles Vaccine; Medical Indigency
PubMed: 18630363
DOI: 10.20529/IJME.2007.018 -
CMAJ : Canadian Medical Association... May 2024
Topics: Humans; Measles; Measles Vaccine; Canada
PubMed: 38802137
DOI: 10.1503/cmaj.240415-f